Pair Name | Resveratrol, Olaparib | ||
Phytochemical Name | Resveratrol (PubChem CID: 445154 ) | ||
Anticancer drug Name | Olaparib (PubChem CID: 23725625 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Resveratrol, Olaparib | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Induction-->DNA damage | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL-xL | hsa598 | |
Down-regulation | Expression | BRCA1 | hsa672 | |
Down-regulation | Expression | PARP1 | hsa142 | |
In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
T-47D | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0553 | |
In Vivo Model | Tumor was induced by injecting MCF-7 cells (1 × 107 in 200 μL sterile 1X PBS) on the right breast fat pads of 6–7 weeks old female BALB/c mice. After formation of tumor, the mice were orally treated with RES + OLA combination (40 mg/kg RES and 20 nM/kg OLA per day) for 30 days. | |||
Result | RES + OLA combination treatment enhanced breast cancer cell death by causing excessive DNA damage and also simultaneously inhibiting the HR pathway. |
No. | Title | Href |
---|---|---|
1 | Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway. Exp Cell Res. 2022 Nov 1;420(1):113338. doi: 10.1016/j.yexcr.2022.113338. | Click |